Abstract
The systemic effects of single and multiple doses of inhaled fluticasone propionate (FP) and budesonide were examined in 24 healthy male volunteers (age range 18–29 years). The study was of an open, placebo-controlled, randomized, three-way crossover design. On each study day, multiple blood samples were taken over a 20 h period after drug administration (after a single dose and after the last of seven doses) and area under the curve (AUC0–20) for plasma cortisol and white blood cell (WBC) counts was calculated. Results: The present study shows that multiple dosing with FP 1.0 mg b.i.d. for 3.5 days (seven doses) resulted in a marked cortisol suppression from placebo which, at 55%, was more than double that seen with a single dose (25% suppression). Multiple dosing with budesonide 0.8 mg b.i.d. resulted in a 34% suppression in plasma cortisol compared with a suppression of 26% with a single dose. The increase in systemic activity of FP after multiple dosing is confirmed by both the number of subjects with 0800 hours plasma cortisol values below normal limits and by the changes in WBC and differential counts. Conclusion: The results of the present study confirm previous findings with regard to the more marked systemic effect of FP following multiple dosing as compared with a single dose. This increase in systemic effect from single dosing to multiple dosing is significantly greater for FP than for budesonide.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dahl R, Lundback B, Malo J-L et al (1993) A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 104:1352–1358
Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL (1993) A comparison of fluticasone propionate, 1mg daily, with beclomethasone dipropionate, 2mg daily, in the treatment of severe asthma. Eur Respir J 6:877–885
Grahnén A, S-Å Eckernäs, Brundin RM, Ling-Andersson A (1994) An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 38:521–525
Barnes PJ, Pedersen S (1993) Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 148:S1-S26
Brown PH, Blundell G, Greening AP, Crompton GK (1991) Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med 85:501–510
Bain BM, Harrison G, Jenkins KD, Pateman AJ, Shenoy EVB (1993) A sensitive radioimmunoassay, incorporating solidphase extraction, for fluticasone 17-propionate in plasma. J Pharm Biomed Analysis 13:557–561
Grove A, Allam C, McFarlane LC, McPhate G, Jackson CM, Lipworth BJ (1994) A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol 38:527–532
Borgström L, Bondesson E, Morén F, Trofast E, Newman SP (1994) Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 7:69–73
Melchor R, Biddescombe MF, Mak VHF, Short MD, Spiro SG (1993) Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 48:506–511
Ryrfeldt Å, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R (1982) Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Resp Dis 63 (Suppl 122):86–95
Brattsand R, Axelsson B (1992) New inhaled glucocorticosteroids. In: Barnes P (ed) New drugs for asthma. IBC Techn Serv, London, pp 192–207
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lönnebo, A., Grahnén, A., Jansson, B. et al. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 49, 459–463 (1996). https://doi.org/10.1007/BF00195931
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00195931